HOME ABOUT US PRINT PUBLICATIONS SUBSCRIPTIONS CONTACT US TELL FRIEND RSS
 
Welcome to FDAweb
Pay Per View
Search our 45,659 - story database FREE
 
Free Items
 Warning Letters
 FDA Notices
 FDA Calendar
 

 FDA Whistleblowers



    








 
 
<< Prev  26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 Next >>
 
TXT Company Asks for Delay in Warning Letter Publication [175 Words] [ Price : $7.95]
An unidentified company asks FDA not to publish a Warning Letter it received until the firm has exhausted its appeals and resolves other issues relating to contents of the letter.
04/10/2013
 
 
TXT Some IVD Test Reviews Take Longer [135 Words] [ Price : $7.95]
An Amplion Research report says that FDA review periods are lengthening for IVD tests using molecular biomarkers.
04/10/2013
 
 
TXT FDA Budget Proposal Boosts Spending by 21% [982 Words] [ Price : $7.95]
President Obama’s FY 2014 budget request boosts FDA’s spending to $4.7 billion, an increase of $821 million (21%) over FY 2012.
04/10/2013
 
 
TXT Merck Gains ‘Breakthrough’ Status for Palbociclib [291 Words] [ Price : $7.95]
FDA grants Pfizer a Breakthrough Therapy designation for palbociclib and its use in treating breast cancer.
04/10/2013
 
 
TXT New Approaches Used to Optimize Protocol Design: Tufts [138 Words] [ Price : $7.95]
Drug industry leaders say growing trial protocol complexity is leading to steps to optimize protocol design.
04/10/2013
 
 
TXT Advisors Say Trulign Lens Safe, Effective [101 Words] [ Price : $7.95]
Members of FDA’s Ophthalmic Devices Panel recommend to the agency that the Bausch & Lomb Trulign lens is safe and its benefits outweigh its risks.
04/09/2013
 
 
TXT Some Accelerated Approval Drugs Face Market Withdrawal [1196 Words] [ Price : $7.95]
CDER cancer drugs director Richard Pazdur, in a wide-ranging discussion with past and present advisory committee leaders, predicts that fast-track new drugs will continue to face market withdrawal, and cost-benefit will continue to not be an FDA approval factor.
04/09/2013
 
 
TXT Von Eschenbach Pushes Device Industry Collaboration [228 Words] [ Price : $7.95]
Former FDA commissioner Andrew von Eschenbach says today’s complex medical problems will only be solved if medical device companies collaborate with each other and share their intellectual property.
04/09/2013
 
 
TXT FDA Extends Review for Delcath’s Melphalan NDA [127 Words] [ Price : $7.95]
FDA extends by three months its review of a Delcath Systems NDA for the Melblez Kit (melphalan) for injection for treating patients with unresectable ocular melanoma metastatic to the liver.
04/09/2013
 
 
TXT WLF Wants Label Case Judgment Tossed [437 Words] [ Price : $7.95]
Washington Legal Foundation asks the Arkansas Supreme Court to throw out a $1.2 billion civil penalty levied by the state against Janssen for failing to include adequate warnings on labels for Risperdal between 2002 and 2006.
04/09/2013
 
 
<< Prev  26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45  Next >>
 

FERDIC INCORPORATED - P.O. Box 28, Camp Hill, PA 17001 | Phone: (717)731-1426 fax:(717)731-1427 Email: info@fdaweb.com